Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial
Introduction In the CASSINI study, rivaroxaban thromboprophylaxis significantly reduced primary venous thromboembolism (VTE) endpoints during the intervention period, but several thromboembolic events designated as secondary efficacy endpoints were not included in the primary analysis. This study wa...
Main Authors: | Alok A. Khorana, Mairéad G. McNamara, Ajay K. Kakkar, Michael B. Streiff, Hanno Riess, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Gerald A. Soff |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2020-04-01
|
Series: | TH Open |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712143 |
Similar Items
-
Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre‐specified subgroup analysis of the randomized CASSINI study
by: Saroj Vadhan‐Raj, et al.
Published: (2020-09-01) -
Efficacy and Safety of Pharmacological Thromboprophylactic Agents for the Prevention of Venous Thromboembolism after Major Abdominal Surgery
by: Al Rawahi, Bader
Published: (2017) -
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
by: Rupert Bauersachs, et al.
Published: (2020-05-01) -
Thromboprophylaxis does not prevent venous thromboembolism after major surgery
by: Adel Attia, et al.
Published: (2015-01-01) -
Thromboembolism and Bleeding in COVID-19
by: Koray Durak
Published: (2021-08-01)